{
    "name": "crizanlizumab",
    "comment": "Rx",
    "other_names": [
        "Adakveo",
        "crizanlizumab-tmca"
    ],
    "classes": [
        "P-Selectin Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/adakveo-crizanlizumab-4000004",
    "pregnancy": {
        "common": [
            "Based on data from animal studies, fetal harm may occur when administered to a pregnant woman",
            "There are insufficient human data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Advise pregnant women of the potential risk to a fetus",
            "Only use during pregnancy if expected benefit justifies the potential risk to the fetus"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In an animal reproduction study, IV administration of crizanlizumab-tmca to pregnant cynomolgus monkeys from onset of organogenesis through delivery resulted in a non-dose-related increased fetal loss (abortions/stillbirths) at doses ~2.8 times the exposure at the recommended clinical dose at 5 mg/kg/dose once q4Weeks"
                ]
            },
            {
                "type": "Disease-associated maternal and/or embryofetal risk ",
                "description": [
                    "Women with sickle cell disease have an increased risk of adverse pregnancy outcomes for the mother and the fetus",
                    "Pregnant women are at greater risk for vasoocclusive crises, preeclampsia, eclampsia, and maternal mortality",
                    "For the fetus, there is an increased risk for intrauterine growth restriction, preterm delivery, low birth weight, and perinatal mortality"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of crizanlizumab-tmca in human or animal milk, the effects on the breastfed child, or the effects on milk production",
            "Maternal IgG is known to be present in human milk",
            "Effects of local gastrointestinal exposure and "
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Infusion-related reactions",
                    "description": [
                        "Infusion-related reactions (defined as occurring within 24 hr of infusion) were observed ",
                        "In the postmarketing setting, cases of infusion-related reactions, including severe pain events, reported, which required hospitalizations; the majority of these infusion-related reactions reported during first and second infusions",
                        "The management of pain events has included acetaminophen, NSAIDs, opioids, antihistamines, intravenous fluids, and/or oxygen therapy",
                        "Some patients have also experienced subsequent complications, such as acute chest syndrome and fat embolism, particularly those treated with steroids",
                        "Monitor for and advise patients of signs and symptoms of infusion-related reactions, which may include pain in various locations, headache, fever, chills, nausea, vomiting, diarrhea, fatigue, dizziness, pruritus, urticaria, sweating, shortness of breath, or wheezing",
                        "Discontinue infusion for severe infusion-related reactions and institute appropriate medical care",
                        "Exercise caution with corticosteroids in patients with sickle cell disease unless clinically indicated (eg, treatment of anaphylaxis)"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Interference with automated platelet counts (platelet clumping) has been observed following administration, in particular when blood samples were collected in tubes containing ethylenediaminetetraacetic acid (EDTA); mitigation strategies are recommended"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "18"
        },
        {
            "name": "Arthralgia",
            "percent": "18"
        },
        {
            "name": "Back pain",
            "percent": "15"
        },
        {
            "name": "Pyrexia",
            "percent": "11"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "24"
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "abdominal pain",
            "percent": null
        },
        {
            "name": "upper abdominal pain",
            "percent": null
        },
        {
            "name": "lower abdominal pain",
            "percent": null
        },
        {
            "name": "abdominal discomfort",
            "percent": null
        },
        {
            "name": "and abdominal tenderness",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "pruritus and vulvovaginal pruritus",
            "percent": null
        },
        {
            "name": "Musculoskeletal chest pain",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Infusion",
            "percent": null
        },
        {
            "name": "site reaction",
            "percent": null
        },
        {
            "name": "infusion",
            "percent": null
        },
        {
            "name": "site extravasation",
            "percent": null
        },
        {
            "name": "infusion",
            "percent": null
        },
        {
            "name": "site pain",
            "percent": null
        },
        {
            "name": "and infusion",
            "percent": null
        },
        {
            "name": "site swelling",
            "percent": null
        },
        {
            "name": "Infusion",
            "percent": null
        },
        {
            "name": "related reaction",
            "percent": null
        },
        {
            "name": "Pain",
            "percent": null
        },
        {
            "name": "in various locations",
            "percent": null
        },
        {
            "name": "occurring during",
            "percent": null
        },
        {
            "name": "within",
            "percent": null
        },
        {
            "name": "hr of infusion",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "potential infusion",
            "percent": null
        },
        {
            "name": "related reactions",
            "percent": null
        }
    ]
}